Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Personnel, Trade Show

Black & Veatch ?Experts on Demand' Service to Offer Food & Beverage, Biotechnology and Bioenergy Expertise


A growing global population and impacts from climate change are challenging the world's food supply chain, making the future of food, beverage and agriculture sectors more exciting ? or unknown. As organizations, engineers, investors and entrepreneurs work to drive sustainability and leverage new advances in biotechnology to ensure a more secure, sustainable food future, Black & Veatch, a global leader in sustainable infrastructure solutions, is expanding its Experts on Demand micro-consulting platform to include three notable experts from the company's rapidly growing NextGen Ag business.

Dr. Kris Chatrathi, David Ziskind and Joerg Blischke bring decades of experience working with Food & Beverage (F&B) industry leaders to Black & Veatch's Experts on Demand micro-consulting service. Their expertise strengthens the range of expertise available to participants across the F&B value chain as they grapple with rapid global transformation across consumer products, food production and agriculture.

"The influx of individuals and companies wanting to leverage biotechnology to address global food security provided a perfect opportunity to connect with dynamic industry experts such as Dr. Chatrathi, Ziskind and Blischke," said Roy Johnson, business strategist with Black & Veatch's NextGen Ag business.

Designed specifically to address client needs in a nimble, agile manner, Experts on Demand offers businesses targeted access to a global network of thousands of professionals, all with deep experience and expertise across the full spectrum of engineering and consulting services. Experts on Demand does not require a long-term contract or consulting engagement; rather, the platform is focused on immediate return on investment ? when and where it's needed.

"Clients are increasingly looking for help solving problems at a faster pace, with lower budgets and shorter delivery times," Johnson said. "Our established Experts on Demand platform provides the opportunity to easily connect these experts with those stakeholders looking to make a difference."

Editor's Notes:

  1. Join NextGen Ag's David Ziskind at this year's virtual 2020 SynBioBeta Conference, The Global Synthetic Biology Summit, where he will be speaking on Considerations for Commercializing your Emerging SynBio Innovation on October 1, 2020 EST.
  2. Learn more about Black & Veatch Experts on Demand.
  3. Learn more about Black & Veatch NextGen Ag.

About Black & Veatch

Black & Veatch is an employee-owned engineering, procurement, consulting and construction company with a more than 100-year track record of innovation in sustainable infrastructure. Since 1915, we have helped our clients improve the lives of people in over 100 countries by addressing the resilience and reliability of our world's most important infrastructure assets. Our revenues in 2019 were US$3.7 billion. Follow us on www.bv.com and on social media.


These press releases may also interest you

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....



News published on and distributed by: